echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > What is the efficacy and safety of the first-line treatment of metastatic lung cancer under the double exemption regimen?

    What is the efficacy and safety of the first-line treatment of metastatic lung cancer under the double exemption regimen?

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *For medical professionals only

    1 minute a day, give you professional "talking points" in the tumor circle! (If you need the original text, you can add Xiaobian WeChat yxj_oncology to obtain)

     

    1

    Jounal of Thoracic Oncology: Navuliyumab plus ipicumab has good safety and efficacy as a first-line treatment option for patients with metastatic non-small cell lung cancer





    4.


    Follow the column



    Subscribe to the column and read a new top issue every day!

    Download the Doctor Station App and subscribe anytime, anywhere
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.